Organizations Filed Purposes:
TO ACHIEVE ITS GOAL OF DEVELOPING A TREATMENT TO SLOW OR REVERSE THE VISION LOSS ASSOCIATED WITH USHER III, THE INITIATIVE HAS PURSUED AN APPROACH THAT FOCUSES ON SMALL MOLECULE CHAPERONE THERAPY.
TO IDENTIFY THERAPIES, TREATMENTS AND A CURE FOR USHER SYNDROME TYPE III.
CONTINUE DEVELOPMENT OF LEAD DRUG COMPOUND TO TREAT USHER SYNDROME TYPE 3, INCLUDING RESEARCH, PRE-CLINICAL SAFETY STUDIES AND MANUFACTURING.
OTHER PROGRAM EXPENSES INCLUDING OVERSIGHT, ADMINISTRATION, EVALUATION AND PATENT REGISTRATION.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Alicia Derrah | TREASURER | 6 | $0 |
| Dr Paul Sternberg Jr | DIRECTOR | 1 | $0 |
| Michael Kraines | DIRECTOR | 1 | $0 |
| Dr David Saperstein | DIRECTOR | 1 | $0 |
| James C Murray | DIRECTOR | 1 | $0 |
| Dr Julia Hayes | DIRECTOR | 1 | $0 |
| Mark Ackermann | DIRECTOR | 1 | $0 |
| Cynthia Elden | PRESIDENT | 6 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202033119349301403_public.xml